Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Shares Outstanding (Diluted Average): 2021-2024

Historic Shares Outstanding (Diluted Average) for Arcturus Therapeutics Holdings (ARCT) over the last 4 years, with Dec 2024 value amounting to $27.0 million.

  • Arcturus Therapeutics Holdings' Shares Outstanding (Diluted Average) rose 0.47% to $27.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.2 million, marking a year-over-year increase of 0.47%. This contributed to the annual value of $27.0 million for FY2024, which is 1.40% up from last year.
  • Latest data reveals that Arcturus Therapeutics Holdings reported Shares Outstanding (Diluted Average) of $27.0 million as of FY2024, which was up 1.40% from $26.6 million recorded in FY2023.
  • Arcturus Therapeutics Holdings' Shares Outstanding (Diluted Average)'s 5-year high stood at $27.1 million during FY2022, with a 5-year trough of $26.3 million in FY2021.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $26.9 million, with a median of $27.0 million in 2024.
  • In the last 5 years, Arcturus Therapeutics Holdings' Shares Outstanding (Diluted Average) grew by 2.95% in 2022 and then dropped by 1.72% in 2023.
  • Arcturus Therapeutics Holdings' Shares Outstanding (Diluted Average) (Yearly) stood at $26.3 million in 2021, then grew by 2.95% to $27.1 million in 2022, then declined by 1.72% to $26.6 million in 2023, then rose by 1.40% to $27.0 million in 2024.